vs

Side-by-side financial comparison of IRONWOOD PHARMACEUTICALS INC (IRWD) and TRUSTCO BANK CORP N Y (TRST). Click either name above to swap in a different company.

TRUSTCO BANK CORP N Y is the larger business by last-quarter revenue ($49.5M vs $47.7M, roughly 1.0× IRONWOOD PHARMACEUTICALS INC). TRUSTCO BANK CORP N Y runs the higher net margin — 32.9% vs -4.8%, a 37.6% gap on every dollar of revenue. Over the past eight quarters, TRUSTCO BANK CORP N Y's revenue compounded faster (6.8% CAGR vs -20.2%).

Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.

TRUSTCO BANK CORP N Y is a regional U.S. financial holding company that provides a full suite of retail and commercial banking products and services, including personal deposit accounts, mortgage loans, small business financing, and wealth management solutions. It primarily operates across New York, Florida, and several other U.S. states, serving individual consumers and small business client segments.

IRWD vs TRST — Head-to-Head

Bigger by revenue
TRST
TRST
1.0× larger
TRST
$49.5M
$47.7M
IRWD
Higher net margin
TRST
TRST
37.6% more per $
TRST
32.9%
-4.8%
IRWD
Faster 2-yr revenue CAGR
TRST
TRST
Annualised
TRST
6.8%
-20.2%
IRWD

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IRWD
IRWD
TRST
TRST
Revenue
$47.7M
$49.5M
Net Profit
$-2.3M
$16.3M
Gross Margin
Operating Margin
14.3%
Net Margin
-4.8%
32.9%
Revenue YoY
-47.3%
Net Profit YoY
-200.9%
14.1%
EPS (diluted)
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRWD
IRWD
TRST
TRST
Q1 26
$49.5M
Q4 25
$47.7M
$48.2M
Q3 25
$122.1M
$47.8M
Q2 25
$85.2M
$46.6M
Q1 25
$41.1M
$45.3M
Q4 24
$90.5M
$43.3M
Q3 24
$91.6M
$43.6M
Q2 24
$94.4M
$43.4M
Net Profit
IRWD
IRWD
TRST
TRST
Q1 26
$16.3M
Q4 25
$-2.3M
$15.6M
Q3 25
$40.1M
$16.3M
Q2 25
$23.6M
$15.0M
Q1 25
$-37.4M
$14.3M
Q4 24
$2.3M
$11.3M
Q3 24
$3.6M
$12.9M
Q2 24
$-860.0K
$12.6M
Operating Margin
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
14.3%
43.7%
Q3 25
61.8%
44.6%
Q2 25
53.2%
42.3%
Q1 25
-70.7%
41.3%
Q4 24
34.8%
34.0%
Q3 24
28.0%
38.8%
Q2 24
26.5%
37.9%
Net Margin
IRWD
IRWD
TRST
TRST
Q1 26
32.9%
Q4 25
-4.8%
32.3%
Q3 25
32.8%
34.0%
Q2 25
27.7%
32.3%
Q1 25
-90.9%
31.5%
Q4 24
2.5%
26.0%
Q3 24
4.0%
29.5%
Q2 24
-0.9%
28.9%
EPS (diluted)
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
$0.01
$0.85
Q3 25
$0.23
$0.86
Q2 25
$0.14
$0.79
Q1 25
$-0.23
$0.75
Q4 24
$0.03
$0.59
Q3 24
$0.02
$0.68
Q2 24
$-0.01
$0.66

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRWD
IRWD
TRST
TRST
Cash + ST InvestmentsLiquidity on hand
$215.5M
Total DebtLower is stronger
$112.9M
Stockholders' EquityBook value
$-261.8M
$670.9M
Total Assets
$396.9M
$6.5B
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
$215.5M
$730.4M
Q3 25
$140.4M
$695.6M
Q2 25
$92.9M
$713.6M
Q1 25
$108.5M
$756.1M
Q4 24
$88.6M
$641.8M
Q3 24
$88.2M
$523.0M
Q2 24
$105.5M
$536.1M
Total Debt
IRWD
IRWD
TRST
TRST
Q1 26
$112.9M
Q4 25
Q3 25
$199.5M
Q2 25
$199.3M
Q1 25
$199.2M
Q4 24
$199.0M
Q3 24
$198.8M
Q2 24
$198.6M
Stockholders' Equity
IRWD
IRWD
TRST
TRST
Q1 26
$670.9M
Q4 25
$-261.8M
$686.6M
Q3 25
$-264.2M
$692.0M
Q2 25
$-308.2M
$692.8M
Q1 25
$-334.1M
$687.8M
Q4 24
$-301.3M
$676.3M
Q3 24
$-311.3M
$669.0M
Q2 24
$-321.7M
$655.2M
Total Assets
IRWD
IRWD
TRST
TRST
Q1 26
$6.5B
Q4 25
$396.9M
$6.4B
Q3 25
$396.1M
$6.3B
Q2 25
$342.9M
$6.3B
Q1 25
$327.2M
$6.3B
Q4 24
$350.9M
$6.2B
Q3 24
$389.5M
$6.1B
Q2 24
$395.6M
$6.1B
Debt / Equity
IRWD
IRWD
TRST
TRST
Q1 26
0.17×
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRWD
IRWD
TRST
TRST
Operating Cash FlowLast quarter
$74.6M
Free Cash FlowOCF − Capex
$74.6M
FCF MarginFCF / Revenue
156.3%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$127.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
$74.6M
$57.6M
Q3 25
$47.6M
$12.8M
Q2 25
$-15.1M
$27.1M
Q1 25
$20.0M
$1.3M
Q4 24
$15.2M
$59.4M
Q3 24
$9.9M
$16.5M
Q2 24
$33.5M
$18.7M
Free Cash Flow
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
$74.6M
$45.7M
Q3 25
$47.6M
$10.0M
Q2 25
$-15.1M
$24.9M
Q1 25
$19.9M
$-3.3M
Q4 24
$54.6M
Q3 24
$9.9M
$15.6M
Q2 24
$33.4M
$17.6M
FCF Margin
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
156.3%
95.0%
Q3 25
39.0%
20.9%
Q2 25
-17.7%
53.5%
Q1 25
48.4%
-7.2%
Q4 24
126.0%
Q3 24
10.8%
35.7%
Q2 24
35.4%
40.5%
Capex Intensity
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
0.0%
24.6%
Q3 25
0.0%
5.9%
Q2 25
0.0%
4.5%
Q1 25
0.1%
10.0%
Q4 24
0.0%
11.3%
Q3 24
0.0%
2.1%
Q2 24
0.1%
2.6%
Cash Conversion
IRWD
IRWD
TRST
TRST
Q1 26
Q4 25
3.70×
Q3 25
1.19×
0.79×
Q2 25
-0.64×
1.80×
Q1 25
0.09×
Q4 24
6.74×
5.27×
Q3 24
2.71×
1.28×
Q2 24
1.49×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IRWD
IRWD

Segment breakdown not available.

TRST
TRST

Net Interest Income$44.7M90%
Noninterest Income$4.8M10%

Related Comparisons